ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Abbott Laboratories has signed a licensing and supply agreement with India’s Zydus Cadila under which it will sell at least 24 Zydus products in 15 emerging markets, with an option to eventually add 40 more. In conjunction with the deal, Abbott has created a stand-alone established-products division that has $5 billion in annual sales of branded generic drugs. The U.S. drug company says roughly 20% of its pharmaceutical sales are derived from emerging markets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter